The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga‐DOTATATE (DOTA‐D Phe1,Tyr3‐octreotate) and 18F‐FDG
Open accessAbstract
BACKGROUND.: The aim was to assess the relevant distribution of the novel PET tracer 68 Ga‐DOTATATE in neuroendocrine tumors (NETs) with combined positron emission tomography / computed tomography (PET/CT) and compare its performance with that of 18 F‐FDG PET/CT. METHODS.: The imaging findings with 68 Ga‐DOTATATE and 18 F‐FDG on 38 consecutive patients with a diagnosis of primary or recurrent NET were compared and correlated with tumor grade on histology based on ki67 and mitotic index. RESULTS.: The sensitivity of 68 Ga‐DOTATATE PET/CT was 82% (31 of 38) and that of 18 F‐FDG PET/CT was 66% (25 of 38). The sensitivity of combined 68 Ga‐DOTATATE and 18 F‐FDG PET/CT was 92% (35 of 38). There was greater uptake of 68 Ga‐DOTATATE than 18 F‐FDG in low‐grade NET (median SUV 29 vs 2.9, P < .001). In high‐grade NET there was higher uptake of 18 F‐FDG over 68 Ga‐DOTATATE (median SUV 11.7 vs 4.4, P = .03). There was a significant correlation with predominant tumor uptake of 68 Ga‐DOTATATE or 18 F‐FDG and tumor grade on histology (P < .0001). CONCLUSIONS.: 68 Ga‐DOTATATE PET/CT is a useful novel imaging modality for NETs and is superior to 18 F‐FDG for imaging well‐differentiated NET. Functional imaging with both 68 Ga‐DOTATATE and 18 F‐FDG has potential for a more comprehensive tumor assessment in intermediate‐ and high‐grade tumors. Cancer 2008. ©2008 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system
Rindi, G., Klöppel, G., Alhman, H., Caplin, M., Couvelard, A., de Herder, W. W., Erikssson, B., Falchetti, A., Falconi, M., Komminoth, P., et al. (2006) · Virchows Archiv · doi:10.1007/s00428-006-0250-1 · Cited by 1,547
Self-citationPeptide Receptors as Molecular Targets for Cancer Diagnosis and Therapy
Reubi, J. C. (2003) · Endocrine Reviews · doi:10.1210/er.2002-0007 · Cited by 1,131
Gabriel, M., Decristoforo, C., Kendler, D., Dobrozemsky, G., Heute, D., Uprimny, C., Kovacs, P., Von Guggenberg, E., Bale, R., & Virgolini, I. J. (2007) · Journal of Nuclear Medicine · doi:10.2967/jnumed.106.035667 · Cited by 1,010
Rindi, G., Klöppel, G., Couvelard, A., Komminoth, P., Körner, M., Lopes, J. M., McNicol, A.-M., Nilsson, O., Perren, A., Scarpa, A., et al. (2007) · Virchows Archiv · doi:10.1007/s00428-007-0452-1 · Cited by 955
The diagnosis and medical management of advanced neuroendocrine tumors.
Kaltsas, G. A., Besser, G. M., & Grossman, A. B. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0014 · Cited by 674
Reubi, J. C., & Waser, B. (2003) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-003-1184-3 · Cited by 592
Hofmann, M., Maecke, H., Börner, A., Weckesser, E., Schöffski, P., Oei, M., Schumacher, J., Henze, M., Heppeler, A., Meyer, G., et al. (2001) · European Journal of Nuclear Medicine · doi:10.1007/s002590100639 · Cited by 544
Adams, S., Baum, R., Rink, T., Schumm-Dräger, P.-M., Usadel, K.-H., & Hör, G. (1997) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s002590050197 · Cited by 387
Caplin, M. E., Buscombe, J. R., Hilson, A. J., Jones, A. L., Watkinson, A. F., & Burroughs, A. K. (1998) · The Lancet · doi:10.1016/s0140-6736(98)02286-7 · Cited by 309
Self-citationKowalski, J. (2003) · Molecular Imaging & Biology · doi:10.1016/s1536-1632(03)00038-6 · Cited by 304
Cited by
Binderup, T., Knigge, U., Loft, A., Federspiel, B., & Kjaer, A. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1759 · Cited by 489
Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors
Hope, T. A., Bergsland, E. K., Bozkurt, M. F., Graham, M., Heaney, A. P., Herrmann, K., Howe, J. R., Kulke, M. H., Kunz, P. L., Mailman, J., et al. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.202275 · Cited by 363
Sadowski, S. M., Neychev, V., Millo, C., Shih, J., Nilubol, N., Herscovitch, P., Pacak, K., Marx, S. J., & Kebebew, E. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.0987 · Cited by 353
18F-FDG PET and PET/CT in the Evaluation of Cancer Treatment Response
Ben-Haim, S., & Ell, P. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.054205 · Cited by 351
Self-citationAdvances in PET imaging of cancer
Schwenck, J., Sonanini, D., Cotton, J. M., Rammensee, H.-G., la Fougère, C., Zender, L., & Pichler, B. J. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-023-00576-4 · Cited by 312
Metadata
- Authors
- Kayani, I., Bomanji, J. B., Groves, A., Conway, G., Gacinovic, S., Win, T., Dickson, J., Caplin, M., & Ell, P. J.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2008-03-28
- Volume
- 112
- Issue
- 11
- Pages
- 2447-2455
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2126350416
- Cited by
- 477
- References
- 20
- FWCI
- 15.55
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga‐DOTATATE (DOTA‐D Phe1,Tyr3‐octreotate) and 18F‐FDG. https://app.cochat.ai/papers/10.1002/cncr.23469
- The paper
- Kayani, I., Bomanji, J. B., Groves, A., Conway, G., Gacinovic, S., Win, T., Dickson, J., Caplin, M., & Ell, P. J. (2008). Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga‐DOTATATE (DOTA‐D Phe1,Tyr3‐octreotate) and 18F‐FDG. Cancer. https://doi.org/10.1002/cncr.23469
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.